Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-07-25
2004-12-07
Stockton, Laura L. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S374000, C514S365000, C546S271400, C548S235000, C548S236000, C548S203000
Reexamination Certificate
active
06828335
ABSTRACT:
FIELD OF THE INVENTION
This invention is directed to indane acetic acid derivatives and their use in pharmaceutical compositions for the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic disease. The invention is also directed to intermediates useful in preparation of indane acetic derivatives and to methods of preparation.
BACKGROUND OF THE INVENTION
Type II diabetes is the more common form of diabetes, with 90-95% of hyperglycemic patients experiencing this form of the disease. In Type II diabetes, there appears to be a reduction in the pancreatic &bgr;-cell mass, several distinct defects in insulin secretion, and a decrease in tissue sensitivity to insulin. The symptoms and consequences of this form of diabetes include fatigue, frequent urination, thirst, blurred vision, frequent infections and slow healing of sores, diabetic nerve damage, retinopathy, micro and macro blood vessel damage, and heart and renal disease.
Resistance to the metabolic actions of insulin is one of the key features of Type II diabetes. Insulin resistance is characterized by impaired uptake and utilization of glucose in insulin-sensitive target organs, for example, adipocytes and skeletal muscle, and by impaired inhibition of hepatic glucose output. Functional insulin deficiency, insulin resistance in the periphery, and the failure of insulin to suppress hepatic glucose output results in fasting hyperglycemia. Pancreatic &bgr;-cells compensate for the insulin resistance by secreting increased levels of insulin. However, the &bgr;-cells are unable to maintain this high output of insulin, and eventually, the glucose-induced insulin secretion falls, leading to the deterioration of glucose homeostasis and to the subsequent development of overt diabetes. Hyperinsulinemia is also linked to insulin resistance, hypertriglyceridemia, low high-density lipoprotein (HDL) cholesterol, and increased plasma concentration of low-density lipoproteins (LDL). The association of insulin resistance and hyperinsulinemia with these metabolic disorders has been termed “Syndrome X,” and has been strongly linked to an increased risk of hypertension and coronary artery disease.
Obesity is an excessive accumulation of adipose tissue. Excess adipose tissue is associated with the development of serious medical conditions, for example, Type II diabetes, hypertension, coronary artery disease, hyperlipidemia, obesity, and certain malignancies. The adipocyte may also influence glucose homeostasis through the production of tumor necrosis factor &agr; (TNF&agr;) and other molecules.
Atherosclerotic disease is known to be caused by a number of factors, for example, hypertension, diabetes, low levels of HDL, and high levels of LDL. Atherosclerotic-related diseases include cardiovascular disease, coronary heart disease (CHD), cerebrovascular disease, and peripheral vessel disease. Coronary heart disease includes CHD death, myocardial infarction, and coronary revascularization. Cerebrovascular disease includes ischemic or hemorrhagic stroke, and transient ischemic attacks.
Accordingly, despite the presence of some pharmaceuticals that are used to treat these diseases, there remains a need for new pharmaceuticals that are both safe and effective agents for the treatment of disease, and for useful methods to prepare them.
The present invention relates to compounds which are useful in the treatment of diabetes and related disorders such as Syndrome X, impaired glucose tolerance, impaired fasting glucose, and hyperinsulinemia; obesity; atherosclerotic disease, dyslipidemia, and related disorders such as hypertriglyceridemia, low HDL cholesterol, and hypercholesteremia; cardiovascular disease; and cerebrovascular disease.
REFERENCES:
patent: 5480896 (1996-01-01), Malamas et al.
patent: 6214850 (2001-04-01), Evans et al.
patent: 0490772 (1992-06-01), None
patent: 9640128 (1996-12-01), None
patent: 0064876 (2000-11-01), None
patent: 0064888 (2000-11-01), None
patent: 0116120 (2001-03-01), None
patent: 0218355 (2002-03-01), None
Subramaniam, The Emerging Role of Thiazolidinediones in the Treatment of Diabetes-Mellitus and Related Disorders, Clin. Exper. Hypertension, 21:121-136, 1999.
Bullock William H.
Coish Philip D. G.
Livingston James N.
Lowe Derek B.
Ma Xin
Bayer Pharmaceuticals Corporation
Pellegrino Susan A.
Stockton Laura L.
LandOfFree
Indane acetic acid derivatives and their use as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indane acetic acid derivatives and their use as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indane acetic acid derivatives and their use as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3283036